MiniMax plans to price its Hong Kong initial public offering at the top of the marketed range, people familiar with the matter said, reflecting investor enthusiasm for Chinese startups that are ...

The 2025 Mini Max High School Award winners for New Jersey were announced by Maxwell Football Club President Mark Dianno on Wednesday. There were 55 players selected from throughout the Garden State.

What if the next big leap in AI wasn’t locked behind corporate paywalls but was instead freely available for anyone to explore, adapt, and innovate with? That’s exactly the promise of MiniMax M2.1, ...

MiniMax, a Chinese rival to OpenAI (OPENAI), unveiled its new M2.1 artificial intelligence model on Tuesday, stating it is “significantly enhanced” over previous offerings. Some of the highlights of ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...